Results 161 to 170 of about 134,100 (245)

A peculiar case of primary lymphoma of pancreas: A rare presentation of Hodgkin lymphoma. [PDF]

Oncoscience
Mohiuddin O, Aibani R, Lalani A, Shabbir F, Aibani A, Sharma V.   +5 more
europepmc   +1 more source

Artificial intelligence for risk assessment and outcome prediction in malignant haematology

British Journal of Haematology, EarlyView.
Machine learning models allow for dynamic and scalable risk stratification and outcome prediction. Different modalities of data such as electronic health records, patient genetics or laboratory results can be used as input. ML models autonomously select features weighing their prognostic value. Methods of model explainability in feature selection allow
Jan‐Niklas Eckardt, Wencke Walter, Jan Moritz Middeke, Torsten Haferlach   +3 more
wiley   +1 more source

The role of liquid biopsy in the management of concurrent Hodgkin lymphoma and ovarian carcinoma treated with nivolumab. [PDF]

Discov Oncol
Hanáčková V, Grohmann J, Urbánková H, Študentová H, Buriánková E, Henzlová L, Papajík T, Bachanová V, Procházka V.   +8 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Methylation-specific qPCR for the EBV C promoter to quantify EBV methylation. [PDF]

Infect Agent Cancer
George L, Rubinstein PG, Petr J, Noy A, Haley L, Adams E, Xian RR, Ambinder RF.   +7 more
europepmc   +1 more source

HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma [PDF]

, 2017
Bianchi, Maurizio, Buffardi, Salvatore, Burnelli, Roberta, Caggiari, Laura, Carosella, Edgardo D., D'Amore, Emanuele Stefano, DE ZORZI, Mariangela, Elia, Caterina, Famengo, Barbara, Farruggia, Piero, Martina, Lia, Mascarin, Maurizio, Muggeo, Paola, Mussolin, Lara, Pillon, Marta, Re, Valli, Sala, Alessandra, Santoro, Nicola, Vinti, Luciana   +18 more
core   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Malignancy in Adults with Inborn Errors of Immunity: A Retrospective Single-Center Study. [PDF]

J Clin Immunol
Gumusburun R, Yıldırım O, Karakoc M, Okan K, Inan S, Dalgıc CT, Akten HS, Bogatekin G, Bulut G, Demir M, Aytac H, Camyar A, Ozısık M, Demir D, Soyer N, Soylu M, Uysal FE, Aykut A, Durmaz A, Ozgul S, Sin AZ, Ardeniz O.   +21 more
europepmc   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non-Hodgkin lymphoma. [PDF]

Oncol Lett
Zhang X, Li G, Liu F, Shi R, Wen J, Wu W, Dai J.   +6 more
europepmc   +1 more source